Amryt Pharma PLC (AMYT)

NASDAQ: AMYT · IEX Real-Time Price · USD
10.64
-0.21 (-1.94%)
Jan 27, 2022 4:00 PM EST - Market closed
Market Cap680.57M
Revenue (ttm)210.24M
Net Income (ttm)-87.54M
Shares Out63.96M
EPS (ttm)-2.24
PE Ration/a
Forward PE67.57
Dividendn/a
Ex-Dividend Daten/a
Volume67,472
Open10.91
Previous Close10.85
Day's Range10.55 - 11.08
52-Week Range9.17 - 15.44
Beta0.07
AnalystsStrong Buy
Price Target34.17 (+221.1%)
Earnings Daten/a

About AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal ...

IndustryDrug Manufacturers-Specialty & Generic
Founded2015
Employees182
Stock ExchangeNASDAQ
Ticker SymbolAMYT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Amryt Pharma stock is "Strong Buy." The 12-month stock price forecast is 34.17, which is an increase of 221.15% from the latest price.

Price Target
$34.17
(221.15% upside)
Analyst Consensus: Strong Buy

News

Amryt Pharma PLC Sponsored ADR (AMYT) Surges 5.5%: Is This an Indication of Further Gains?

Amryt Pharma PLC Sponsored ADR (AMYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher ...

1 week ago - Zacks Investment Research

Amryt Announces New Patents for Oleogel-S10

Amryt Announces New Patents for Oleogel-S10

1 week ago - GlobeNewsWire

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in th...

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment wit...

2 weeks ago - GlobeNewsWire

Key Dates for AIM Delisting

Amryt Pharma plc - Key Dates for AIM Delisting

3 weeks ago - GlobeNewsWire

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral oct...

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa ® (oral octreotide) in Acromegaly P atients

3 weeks ago - GlobeNewsWire

Director/PDMR Shareholding

Amryt Pharma plc

1 month ago - GlobeNewsWire

Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA t...

2 months ago - Zacks Investment Research

Amryt Provides Update on Regulatory Review Process for Oleogel-S10

Amryt Provides Update on Regulatory Review Process for Oleogel-S10

2 months ago - GlobeNewsWire

Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPE...

2 months ago - GlobeNewsWire

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Tops Revenue Estimates

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 66.67% and 7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for t...

2 months ago - Zacks Investment Research

Amryt Reports Strong Q3 2021 Results

Amryt Reports Strong Q3 2021 Results

2 months ago - GlobeNewsWire

Earnings Preview: Amryt Pharma PLC Sponsored ADR (AMYT) Q3 Earnings Expected to Decline

Amryt Pharma PLC Sponsored ADR (AMYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3

A mryt to Report Q 3 202 1 Results and Host Conference Call & Webcast on November 3

3 months ago - GlobeNewsWire

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

3 months ago - GlobeNewsWire

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M

4 months ago - GlobeNewsWire

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT

5 months ago - GlobeNewsWire

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

5 months ago - GlobeNewsWire

Result of General Meetings

DUBLIN, Ireland, and Boston MA, July 28, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatmen...

5 months ago - GlobeNewsWire

Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6

Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6

6 months ago - GlobeNewsWire

Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual ...

Publication of Circular to Amryt S hareholders in relation to the acquisition of Chiasma, Inc . , and p osting of Annual Report and Notice s of General Meeting s

7 months ago - GlobeNewsWire

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acqui...

Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.

7 months ago - GlobeNewsWire

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting

7 months ago - GlobeNewsWire

Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review

Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.

7 months ago - Zacks Investment Research

Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder

The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatme...

7 months ago - Benzinga

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

7 months ago - GlobeNewsWire